Omniderm 1%+0.1%15 gm

Omniderm 1%+0.1% is a combination topical cream indicated for the short-term treatment of inflammatory fungal skin infections where both antifungal and anti-inflammatory action are needed. This is an established use, supported by clinical and regulatory data.

• Tinea pedis (athlete's foot) with significant inflammation
• Tinea cruris (jock itch) with significant inflammation
• Tinea corporis (ringworm) with significant inflammation
• Cutaneous candidiasis with an inflammatory component

Omniderm 1%+0.1% is intended only for cases where superficial dermatophyte or yeast infection is accompanied by marked inflammation and itching; once inflammation subsides, treatment should continue, if needed, with an antifungal-only product. It is not a first-line treatment for uncomplicated fungal infections without inflammation, and is generally not recommended for diaper rash in infants and young children (see Precautions and Pediatric Use).

Each gram of Econazole Nitrate + Triamcinolone Acetonide cream typically contains:

• Econazole Nitrate USP equivalent to econazole 10 mg (1% w/w)
• Triamcinolone Acetonide USP 1 mg (0.1% w/w)

in a suitable cream base. Strength and excipients may vary slightly by manufacturer; refer to the specific product label for exact composition.

Omniderm 1%+0.1% is a fixed-dose combination topical preparation that pairs a broad-spectrum imidazole antifungal (econazole nitrate) with a synthetic corticosteroid (triamcinolone acetonide). The combination is formulated to provide simultaneous antifungal activity against dermatophytes, yeasts (including Candida), and certain gram-positive bacteria, along with anti-inflammatory, anti-pruritic, and anti-allergic effects. Omniderm 1%+0.1% is intended for short-term application to reduce both the causative fungal organism and the associated inflammation, itching, and discomfort of the skin lesion.

Topical Antifungal and Corticosteroid Combination — Omniderm 1%+0.1% combines an imidazole-derivative antifungal with a mid-to-high potency synthetic corticosteroid for dermatological use.

Econazole Nitrate + Triamcinolone Acetonide combines two agents with complementary actions:

• Econazole nitrate is a broad-spectrum imidazole antifungal that inhibits ergosterol synthesis in the fungal cell membrane, increasing membrane permeability and causing leakage of essential intracellular components, leading to fungal cell death. It is active against dermatophytes (Trichophyton, Microsporum, Epidermophyton species), yeasts (including Candida albicans), Malassezia furfur, and some gram-positive bacteria.
• Triamcinolone acetonide is a synthetic corticosteroid that suppresses the inflammatory response by inhibiting the release of inflammatory mediators, reducing capillary permeability, and causing vasoconstriction. This produces anti-inflammatory, anti-pruritic, and anti-allergic effects, relieving redness, swelling, and itching associated with the fungal infection.

Together, these actions in Econazole Nitrate + Triamcinolone Acetonide allow more rapid symptomatic relief than an antifungal agent alone, while treating the underlying fungal infection.

For topical use on the skin only — not for oral, ophthalmic, intravaginal, or intranasal use.

• Clean and dry the affected area before application.
• Apply a thin film of Omniderm 1%+0.1% and gently rub in until mostly absorbed.
• Wash hands after application unless the hands are the treated area.
• Do not apply under occlusive dressings, bandages, tight clothing, or diapers/plastic pants unless specifically directed by a physician, as occlusion significantly increases systemic absorption.
• Avoid contact with the eyes, mouth, and mucous membranes.
• Do not use on the face unless specifically directed by a physician, due to increased risk of skin thinning in this area.

Clinically significant drug-drug interactions with topically applied Omniderm 1%+0.1% are uncommon because systemic absorption from intact, non-occluded skin is generally low. However, the following should be noted:

• Concurrent use of other topical products (especially other corticosteroids or occlusive agents) on the same area may increase local irritation or systemic corticosteroid absorption.
• Applying Omniderm 1%+0.1% under occlusion, over large body surface areas, or on broken/damaged skin substantially increases systemic absorption and raises the theoretical risk of interactions relevant to systemic corticosteroids (e.g., with other systemic corticosteroids, or drugs affecting the HPA axis).
• No clinically significant interactions have been established for the topical (non-occluded) use of this combination; if significant systemic absorption occurs (e.g., in infants, over large areas, or with prolonged use), treat interactions as for systemic corticosteroid therapy and consult a physician.

Most adverse effects with Omniderm 1%+0.1% are local and mild, occurring at the application site:

• Burning, stinging, or itching sensation
• Redness (erythema) or irritation
• Dryness or peeling of the skin
• Folliculitis (inflammation of hair follicles)
• Rarely, allergic contact dermatitis to a component of the cream

With prolonged or inappropriate use (beyond the recommended duration, under occlusion, or over large areas), corticosteroid-related effects may occur, including:

• Skin atrophy (thinning), striae (stretch marks), and telangiectasia (visible small blood vessels)
• Hypopigmentation at the application site
• Systemic absorption leading to HPA-axis suppression, particularly in infants and young children (see Precautions and Warnings)

Patients should stop use and consult a physician if signs of hypersensitivity, worsening infection, or significant skin changes occur.

Pregnancy: There are limited controlled data on the use of Omniderm 1%+0.1% in human pregnancy. Topical corticosteroids can be absorbed systemically and may be associated with fetal risk when used in large amounts or for prolonged periods. Omniderm 1%+0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, at the lowest effective dose, for the shortest necessary duration, and under medical supervision.

Lactation: It is not known whether topically applied triamcinolone acetonide is excreted in human breast milk in clinically significant amounts; econazole may be excreted in negligible amounts. As a precaution, Omniderm 1%+0.1% should not be applied to the breast/nipple area before breastfeeding, and use elsewhere on the body should be limited to the smallest effective amount for the shortest duration, under physician guidance.

Omniderm 1%+0.1% is intended for short-term use only — treatment should generally not exceed about 2 weeks. If there is no visible improvement within the expected treatment period, discontinue the product and consult a physician rather than continuing use indefinitely.

• Not for the face unless specifically directed by a physician, due to increased risk of skin thinning, striae, and telangiectasia on facial skin.
• Avoid occlusion: do not apply under airtight dressings, bandages, tight-fitting clothing, or diapers/plastic pants, as occlusion markedly increases systemic corticosteroid absorption and the risk of HPA-axis suppression.
• Not recommended for diaper rash in infants and young children, as the diaper itself acts as an occlusive dressing, greatly increasing systemic absorption risk.
• Avoid use on large body surface areas or for prolonged periods, which similarly increase systemic absorption and risk of adrenal suppression.
• Infants and young children are at greater risk of HPA-axis suppression, growth retardation, delayed weight gain, and Cushingoid features due to a larger skin-surface-to-body-weight ratio; use in this population requires close physician supervision (see Pediatric Use).
• Not for use on active viral skin infections (herpes simplex, varicella) — see Contraindications.
• Discontinue if signs of hypersensitivity or local irritation develop, or if the infection appears to worsen or spread.
• Avoid contact with the eyes; if accidental eye contact occurs, rinse thoroughly with water and seek medical advice if irritation persists.

Topical overdose with Omniderm 1%+0.1% is unlikely with correct use, but excessive or prolonged application, especially under occlusion or over large areas, may lead to increased local irritation and systemic corticosteroid effects (including HPA-axis suppression). If applied excessively, wash off the excess cream with lukewarm water.

If the product is accidentally ingested (e.g., by a child), seek medical attention promptly; treatment is generally supportive and symptomatic, as directed by a physician or poison control center.

If accidental contact with the eyes occurs, rinse thoroughly with clean water or saline and seek medical attention if irritation or visual symptoms persist.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze.

Pediatric patients: Use of Omniderm 1%+0.1% in children should be limited to the smallest effective amount, on the smallest necessary area, for the shortest duration, and only under close physician supervision, due to a higher risk of HPA-axis suppression than in adults. Generally not recommended for diaper rash in infants (see Pediatric Uses).

Elderly patients: No specific dose adjustment is typically required; skin may be thinner and more prone to corticosteroid-related atrophy, so use the lowest effective amount for the shortest duration.

Renal or hepatic impairment: No specific dosage adjustment data are available; systemic absorption from topical use is normally minimal, but caution is advised with extensive application.

Immunocompromised patients: Use with caution and under medical supervision, as corticosteroid effects may mask signs of worsening or secondary infection.

Omniderm 1%+0.1% is intended for short-term use only. In most patients and body areas, treatment should not continue beyond approximately 2 weeks. Prolonged or continuous use, especially under occlusion (including diapers), on large body surface areas, or on the face and skin folds, increases the risk of skin atrophy, striae, telangiectasia, and systemic corticosteroid absorption with HPA-axis suppression. If the skin lesion has not improved noticeably within the expected treatment period, treatment should be stopped and a physician consulted for reassessment, rather than continuing the product indefinitely. Once inflammation has resolved, if further antifungal treatment is needed, an antifungal-only product should be used instead of continuing the combination.

Econazole Nitrate + Triamcinolone Acetonide belongs to the drug class of Topical Antifungal–Corticosteroid Combinations, combining an imidazole-derivative antifungal (econazole nitrate) with a synthetic glucocorticoid (triamcinolone acetonide).

Econazole Nitrate + Triamcinolone Acetonide works through two complementary mechanisms: econazole nitrate disrupts fungal cell membrane synthesis by inhibiting ergosterol production, leading to fungal cell death, while triamcinolone acetonide suppresses local inflammation by inhibiting inflammatory mediator release and causing vasoconstriction, reducing redness, swelling, and itching.

C

Omniderm 1%+0.1% requires particular caution in pediatric patients. Infants and young children have a larger skin-surface-area-to-body-weight ratio than adults, making them more susceptible to systemic absorption of the corticosteroid component and resulting HPA-axis suppression, which can present as reduced cortisol response, growth retardation, delayed weight gain, or Cushingoid features (e.g., moon face, weight gain).

• Omniderm 1%+0.1% should generally NOT be used for diaper rash in infants and young children, because the diaper functions as an occlusive dressing that greatly increases systemic corticosteroid absorption.
• If use in a child is considered necessary by a physician, it should be limited to the smallest effective amount, applied to the smallest area necessary, for the shortest possible duration (generally under 2 weeks), and avoid occlusive dressings, tight clothing, or plastic pants over the treated area.
• Pediatric use should occur only under close physician supervision, with monitoring for local and systemic corticosteroid effects.
• Safety and efficacy in neonates have not been established; avoid use in this age group unless specifically directed by a physician.